Study suggests cancer patients may be receiving higher doses and longer treatment courses than needed

Recent analysis highlighted that many cancer patients are being treated with larger drug doses and extended therapy durations than may be medically necessary.

The pattern raises concerns about unnecessary exposure to toxic side effects and adds substantial cost to already expensive oncology care.

The piece also points to unrelated market activity, including a sharp swing in Moderna's stock driven by profit taking, and notes the expanding use of artificial intelligence in scientific writing.